Media Release

Basel, 27 April 2017

Roche reports a good start in 2017

- Group sales increase 4%[1] at constant exchange rates and in Swiss francs
- Pharmaceuticals Division sales up 3%, driven mainly by Tecentriq and Perjeta
- Diagnostics Division sales grow 6%, primarily due to immunodiagnostic solutions
- US FDA approves Ocrevus to treat two forms of multiple sclerosis
- EU approves Alecensa for the treatment of a specific form of lung cancer
- Successful phase III Aphinity study of Perjeta treatment regimen in early breast cancer
- Outlook for 2017 confirmed

Sales	**CHF millions**		**As % of sales**		**% change**	
January - March 2017	**2017**	**2016**	**2017**	**2016**	**At CER**	**In CHF**
Group sales	12,942	12,414	100	100	+4	+4
Pharmaceuticals Division	10,177	9,800	79	79	+3	+4
United States	5,070	4,716	39	38	+6	+8
Europe	2,273	2,319	18	19	+1	-2
Japan	856	853	7	7	-2	0
International*	1,978	1,912	15	15	+1	+3
Diagnostics Division	2,765	2,614	21	21	+6	+6

*Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

[1] Unless otherwise stated, all growth rates in this document are at constant exchange rates (CER: average 2016).

F. Hoffmann-La Roche Ltd
4070 Basel
Switzerland
Group Communications
Roche Group Media Relations
Tel. +41 61 688 88 88
www.roche.com

Commenting on the Group's results, Roche CEO Severin Schwan said: «We have started the year with good growth in both our Pharmaceuticals and Diagnostics Divisions and with important positive clinical study results. A highlight of the first quarter was the US approval of our medicine Ocrevus for the treatment of multiple sclerosis (MS). Ocrevus is the first and only FDA approved medicine for both relapsing and primary progressive forms of MS and represents a new era for the treatment of this disease. We are well on track to meet our full-year targets.»

Group results

Good sales growth in both divisions

Group sales rose 4% to CHF 12.9 billion. Sales in the Pharmaceuticals Division increased 3% to CHF 10.2 billion, driven by very good early uptake of Tecentriq and continued strong growth of Perjeta and partially offset by lower sales of Tamiflu. In the US, sales advanced 6%, led by the recently launched medicines Tecentriq and Alecensa, as well as Xolair and MabThera/Rituxan. Sales of Tamiflu declined due to competition from generics. In Europe (+1%), Perjeta, Actemra/RoActemra and Herceptin were the main contributors to sales growth. In the International region, sales advanced 1%, led by the Latin America and Asia–Pacific subregions. In Japan (-2%), sales were impacted by government price reductions in April 2016.

Diagnostics Division sales increased 6% to CHF 2.8 billion. Centralised and Point of Care Solutions[2] was the main contributor, led by the growth of its immunodiagnostics business (+13%). In regional terms, growth was driven in particular by Asia–Pacific (+13%) and Latin America (+21%). In EMEA[3] (+2%) and Japan (+4%), sales increases were led by Centralised and Point of Care Solutions, and in North America (+4%) by Tissue Diagnostics.

Important new product approvals in Pharmaceuticals

The US Food and Drug Administration (FDA) approved Ocrevus for the treatment of two forms of multiple sclerosis (MS); relapsing MS (RMS) and primary progressive MS (PPMS). Ocrevus is an important new treatment option for people with RMS, and due to the favourable benefit-risk profile has the potential to change disease course. It is also the first and only medicine approved to treat PPMS, a particularly disabling form of MS. Multiple sclerosis, for which there is currently no cure,[4] is a chronic disease that affects an estimated 2.3 million people around the world. The European Commission granted Alecensa a conditional marketing authorisation as monotherapy for adult patients with ALK[5]-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

---

[2] Formerly Roche Professional Diagnostics

[3] EMEA = Europe, Middle East and Africa

[4] Multiple Sclerosis International Federation. (2013). Atlas of MS 2013. Available at: http://www.msif.org/about-us/advocacy/atlas/.

[5] ALK = anaplastic lymphoma kinase

Clinical trial results support key new indications for Roche medicines

Roche communicated important clinical results in the first quarter of 2017. The phase III Aphinity study with Roche's Perjeta regimen met its primary endpoint. It showed that adjuvant (after surgery) treatment with the combination of Perjeta, Herceptin and chemotherapy achieved a statistically significant reduction in the risk of recurrence of invasive disease or death in people with HER2-positive early breast cancer compared with Herceptin and chemotherapy alone. Encouraging results from the Tecentriq phase II study IMmotion 150 were presented: the study compared Tecentriq plus Avastin as well as Tecentriq monotherapy to the treatment with sunitinib in people with previously untreated, locally advanced or metastatic renal cell carcinoma.

The phase III Alur study met its primary endpoint, showing that Alecensa significantly improved progression-free survival (PFS) in people with ALK-positive advanced NSCLC who had progressed following treatment with platinum-based chemotherapy and crizotinib, compared with chemotherapy. In addition, in early April Roche announced that the phase III Alex study met its primary endpoint, showing that Alecensa as initial (first-line) treatment significantly improved PFS compared with crizotinib in people with ALK-positive NSCLC.

The US FDA accepted Roche's supplemental Biologics License Application and granted priority review for Actemra/RoActemra for giant cell arteritis (GCA), a form of vasculitis. The FDA also granted breakthrough therapy designation for MabThera/Rituxan, in pemphigus vulgaris, a rare skin disease.

New generation of diagnostics products

The cobas HPV DNA test for cobas 6800/8800 systems was launched in the EU and other markets accepting the CE-mark, and the US FDA cleared the CINtec Histology test to aid in the diagnosis of cervical pre-cancer. These tests are a key part of Roche's cervical cancer prevention portfolio. Human papillomavirus (HPV) is the cause of almost all cases of cervical cancer, a leading cause of death in women.

The cobas Liat PCR system was launched in markets accepting the CE-mark. This real-time PCR system covers four assays, including a test for the rapid detection of *Clostridium difficile.* Timely and accurate diagnosis of this infection is important because it can quickly become life-threatening. In the US, the FDA approved Roche's cobas e 801 module for high-volume immunology testing. The Accu-Chek Instant system for effortless, reliable and affordable blood glucose monitoring was introduced in various markets in the EU.

Outlook for 2017 confirmed

In 2017, Roche expects sales to grow low- to mid-single digit, at constant exchange rates. Core earnings per share are targeted to grow broadly in line with sales, at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.

Pharmaceuticals Division

Top-selling pharmaceuticals January - March 2017	Total		United States		Europe		Japan		International*	
	CHFm	%	CHFm	%	CHFm	%	CHFm	%	CHFm	%
MabThera/Rituxan	1,899	4	1,045	6	465	1	62	-3	327	4
Herceptin	1,756	2	680	3	522	3	67	-4	487	0
Avastin	1,684	-2	765	-2	446	-3	181	-8	292	7
Perjeta	524	19	257	14	176	21	26	7	65	47
Actemra/RoActemra	445	15	177	21	147	17	64	4	57	7
Xolair	437	22	437	22	0	0	0	0	0	0
Lucentis	392	9	392	9	0	0	0	0	0	0
Activase/TNKase	316	13	305	14	0	0	0	0	11	0
Tamiflu	270	-27	156	-39	13	-30	65	5	36	-4
Kadcyla	222	11	89	11	84	5	16	-9	33	49

* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

Key pharmaceutical products in 2017

Herceptin, Perjeta and **Kadcyla** (combined +6%). For HER2-positive breast cancer and HER2-positive metastatic gastric cancer (Herceptin only). **Herceptin** sales were up 2%, led by growth in Brazil and the US and helped by additional reimbursement approvals and broader use in China. **Perjeta** (+19%) experienced strong sales growth in Europe and the US. Sales of **Kadcyla** (+11%) were fuelled by increasing uptake in International region countries where the medicine was recently launched and in the US.

MabThera/Rituxan (+4%). For common forms of blood cancer, rheumatoid arthritis and certain types of vasculitis. Sales continued to rise despite competitive pressure. Increasing sales were seen mainly in the US and the International region. Growth in China was supported by additional reimbursement approvals and expanded regional access, mainly in diffuse large B cell lymphoma.

Avastin (-2%). For advanced colorectal, breast, lung, kidney, cervical and ovarian cancer, and relapsed glioblastoma (a type of brain tumour). Sales continued to grow in the International region (+7%). In the US, where Avastin is already broadly used in its approved indications, sales declined 2%, largely due to growing use of new cancer immunotherapy agents in lung cancer.

Actemra/RoActemra (+15%). For rheumatoid arthritis and forms of juvenile idiopathic arthritis. Increasing use of Actemra/RoActemra as a single agent (monotherapy) and of the subcutaneous formulation of the medicine remained a key growth driver globally. Actemra/RoActemra remains the leader in monotherapy in the five largest EU markets.

Esbriet (+13%). For idiopathic pulmonary fibrosis (IPF). Sales continued to expand, mostly due to increasing use in people with moderate and progressive disease.

Gazyva/Gazyvaro (+48%). For chronic lymphocytic leukaemia (CLL) and rituximab-refractory follicular lymphoma. Sales expanded in all regions where this product has been launched, despite increasing competition in CLL.

Recently launched Roche medicines recorded good sales performance in the first quarter. **Tecentriq sales totalled** CHF 113 million; following FDA approval of the medicine in bladder and lung cancer in 2016, market uptake in the US has been very good. **Alecensa** (CHF 68 million), for people with ALK-positive advanced NSCLC whose disease has progressed on, or who are intolerant to crizotinib, showed very good uptake in the US and sales growth remained strong in Japan.

Diagnostics Division

Sales January - March 2017	CHF millions		As % of sales		% change	
	2017	2016	2017	2016	At CER	In CHF
Diagnostics Division	2,765	2,614	100	100	+6	+6
Business Areas:						
Centralised and Point of Care Solutions	1,641	1,519	59	58	+9	+8
Diabetes Care	447	443	16	17	+1	+1
Molecular Diagnostics	441	446	16	17	-2	-1
Tissue Diagnostics	236	206	9	8	+15	+15
Regions:						
Europe, Middle East, Africa	1,126	1,130	41	43	+2	0
North America	740	703	27	27	+4	+5
Asia–Pacific	594	529	21	20	+13	+12
Latin America	203	157	7	6	+21	+29
Japan	102	95	4	4	+4	+7

Centralised and Point of Care Solutions (+9%) was the largest contributor to the division's sales performance, led by the Asia–Pacific region, with continued strong growth in China (+23%). Integrated Serum Work Area solutions, comprising the immunodiagnostics (+13%) and clinical chemistry (+3%) segments, were the main drivers of this growth. Already available in the EU and markets accepting the CE-mark, the cobas e 801 module, for immunodiagnostics, was approved in the US. The new system doubles the currently available immunochemistry testing capacity over the same floor space, requires only low sample volume, and delivers fast results. The recently launched cobas m 511 integrated haematology analyser has been very well received by customers.

Sales in **Molecular Diagnostics,** including sequencing, declined 2%. HPV screening sales advanced 3%. In virology, which includes Roche's portfolio for the diagnosis and monitoring of hepatitis B, hepatitis C and HIV, sales declined 6%, impacted by the phasing of certain testing programmes by non-government organisations and a base effect from prior year strong HCV sales. Sales in the blood screening business (-4%) were affected by the timing of tender renewals in several markets.

The cobas HPV DNA test adds to the growing CE-IVD menu on the cobas 6800/8800 systems and enables laboratories to run HPV DNA testing simultaneously with our portfolio of other previously released cobas assays. The cobas Liat System for point-of-care testing includes Europe's first real-time PCR test for suspected infections with *Clostridium difficile* and provides results in less than 20 minutes.

Tissue Diagnostics sales increased 15%, driven strongly by sales in North America and EMEA. Sales in the advanced staining portfolio and in primary staining were up 11% and 14%, respectively. The companion diagnostics business grew 40%. The CINtech Histology test, now approved by the FDA, completes the cervical cancer testing portfolio in the US.

Roche's unique combination of molecular, cellular and tissue-based diagnostic tests for screening and diagnosis of HPV infection provides healthcare professionals with important information to help them make patient care decisions and minimise unnecessary treatment.

Diabetes Care sales increased 1%, supported by the launch of the Accu-Chek Guide and the Accu-Chek Instant systems for strip-based blood glucose testing and management. Higher sales were recorded in Latin America. Sales were stable in the EMEA and North America regions, and declined in Asia–Pacific and Japan.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Additional information

- Media Release online: http://www.roche.com/med-cor-2017-04-27.htm
- Diagnostics: key product launches in 2017: http://www.roche.com/diaq117.pdf
- Annual Report: www.roche.com/annual_reports
- Dow Jones Sustainability Indices: www.sustainability-indexes.com

Roche Group Media Relations

Phone: +41 -61 688 8888 / e-mail: media.relations@roche-global.com

- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Simone Oeschger
- Anja von Treskow

Appendix: Tables

1. Sales January to March 2017 and 2016

CHF millions	Three months ended 31 March		% change	
	2017	2016	At CER	In CHF
Pharmaceuticals Division	10,177	9,800	3	4
United States	5,070	4,716	6	8
Europe	2,273	2,319	1	-2
Japan	856	853	-2	0
International*	1,978	1,912	1	3
Diagnostics Division	2,765	2,614	6	6
Roche Group	12,942	12,414	4	4

* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

2. Quarterly sales and constant exchange rate sales growth by Division in 2017 and 2016

CHF millions	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015	Q3 2016	% change vs. Q3 2015	Q4 2016	% change vs. Q4 2015	Q1 2017	% change vs. Q1 2016
Pharmaceuticals Division	9,800	4	9,660	5	9,680	2	9,963	3	10,177	3
United States	4,716	3	4,557	5	4,577	1	4,744	3	5,070	6
Europe	2,319	5	2,320	6	2,277	5	2,243	2	2,273	1
Japan	853	4	903	1	934	-3	1,021	3	856	-2
International*	1,912	4	1,880	5	1,892	2	1,955	3	1,978	1
Diagnostics Division	2,614	5	2,948	8	2,803	8	3,108	5	2,765	6
Roche Group	12,414	4	12,608	6	12,483	3	13,071	3	12,942	4

*Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

3. Pharmaceuticals Division

Top-selling pharmaceuticals and recent new launches	Total		United States		Europe		Japan		International*	
January - March 2017	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	1,899	4	1,045	6	465	1	62	-3	327	4
Herceptin	1,756	2	680	3	522	3	67	-4	487	0
Avastin	1,684	-2	765	-2	446	-3	181	-8	292	7
Perjeta	524	19	257	14	176	21	26	7	65	47
Actemra/RoActemra	445	15	177	21	147	17	64	4	57	7
Xolair	437	22	437	22	-	-	-	-	-	-
Lucentis	392	9	392	9	-	-	-	-	-	-
Activase/TNKase	316	13	305	14	-	-	-	-	11	0
Tamiflu	270	-27	156	-39	13	-30	65	5	36	-4
Kadcyla	222	11	89	11	84	5	16	-9	33	49

Recent new launches										
Esbriet	202	13	153	19	42	-2	-	-	7	10
Tecentriq	113	-	109	-	2	-	-	-	2	-
Alecensa	68	124	36	244	1	-	29	50	2	-
Gazyva	67	48	38	27	17	59	-	-	12	160
Cotellic	14	37	4	87	9	5	-	-	1	-

* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

4. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth Q1 2017 vs. Q1 2016

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	1,899	4	1,045	6	465	1	62	-3	327	4
Herceptin	1,756	2	680	3	522	3	67	-4	487	0
Avastin	1,684	-2	765	-2	446	-3	181	-8	292	7
Perjeta	524	19	257	14	176	21	26	7	65	47
Actemra/RoActemra	445	15	177	21	147	17	64	4	57	7
Xolair	437	22	437	22	-	-	-	-	-	-
Lucentis	392	9	392	9	-	-	-	-	-	-
Activase/TNKase	316	13	305	14	-	-	-	-	11	0
Tamiflu	270	-27	156	-39	13	-30	65	5	36	-4
Kadcyla	222	11	89	11	84	5	16	-9	33	49
Tarceva	211	-19	109	-21	37	-22	22	-4	43	-18
Esbriet	202	13	153	19	42	-2	-	-	7	10
Pulmozyme	175	9	125	10	32	10	-	-	18	3
CellCept	170	-10	33	-26	43	3	17	9	77	-11
Mircera	115	-4	-	-	22	3	43	-6	50	-5
Tecentriq	113	-	109	-	2	-	-	-	2	-
Xeloda	104	-7	6	30	6	-28	25	-3	67	-8
Madopar	86	18	-	-	23	0	4	-2	59	30
NeoRecormon/Epogin	77	-3	-	-	32	-8	10	-6	35	4
Rocephin	74	-9	-	-	13	-3	6	-15	55	-10

* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015	Q3 2016	% change vs. Q3 2015	Q4 2016	% change vs. Q4 2015	Q1 2017	% change vs. Q1 2016
MabThera/Rituxan	1,825	3	1,877	5	1,782	0	1,816	2	1,899	4
Herceptin	1,725	4	1,709	5	1,691	4	1,657	0	1,756	2
Avastin	1,706	4	1,724	4	1,684	-3	1,669	-4	1,684	-2
Perjeta	439	33	467	35	473	24	467	14	524	19
Actemra/RoActemra	386	14	428	21	433	15	450	14	445	15
Xolair	356	22	375	17	389	13	378	8	437	22
Lucentis	355	-13	349	-10	373	-1	329	-14	392	9
Activase/TNKase	276	21	261	17	270	12	301	15	316	13
Tamiflu	367	-6	43	5	93	-23	291	72	270	-27
Kadcyla	201	11	207	10	208	5	215	2	222	11
Tarceva	258	-14	262	-17	245	-18	259	-11	211	-19
Esbriet	178	96	180	24	213	35	197	10	202	13
Pulmozyme	160	7	177	10	167	0	181	1	175	9
CellCept	189	-4	184	-5	186	-5	182	-10	170	-10
Mircera	118	0	123	7	134	-16	137	23	115	-4
Tecentriq	-	-	19	-	58	-	80	-	113	-
Xeloda	111	-17	119	-5	120	-6	156	18	104	-7
Madopar	71	20	69	-4	74	4	76	6	86	18
NeoRecormon/Epogin	79	-14	82	-8	83	-7	84	-7	77	-3
Rocephin	82	5	75	18	75	18	66	-9	74	-9

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015	Q3 2016	% change vs. Q3 2015	Q4 2016	% change vs. Q4 2015	Q1 2017	% change vs. Q1 2016
MabThera/Rituxan	978	0	1,023	6	932	-3	978	3	1,045	6
Herceptin	651	4	630	6	617	0	611	1	680	3
Avastin	775	-2	763	0	723	-9	703	-10	765	-2
Perjeta	224	15	230	16	229	8	222	1	257	14
Actemra/RoActemra	145	12	164	23	165	13	173	11	177	21
Xolair	356	22	375	17	389	13	378	8	437	22
Lucentis	355	-13	349	-10	373	-1	329	-14	392	9
Activase/TNKase	265	21	250	18	258	12	289	16	305	14
Tamiflu	251	-15	12	-45	63	-39	141	16	156	-39
Kadcyla	79	-2	80	7	79	-1	78	-2	89	11
Tarceva	136	-15	141	-17	135	-16	148	-8	109	-21
Esbriet	127	145	134	32	158	38	150	19	153	19
Pulmozyme	112	6	121	7	116	0	125	-4	125	10
CellCept	45	0	43	-18	46	-13	38	-31	33	-26
Mircera	-	-	-	-	-	-	-	-	-	-
Tecentriq	-	-	19	-	57	-	78	-	109	-
Xeloda	5	-71	12	-24	10	-21	52	312	6	30
Madopar	-	-	-	-	-	-	-	-	-	-
NeoRecormon/Epogin	-	-	-	-	-	-	-	-	-	-
Rocephin	-	-	-	-	1	-	-	-	-	-

* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015	Q3 2016	% change vs. Q3 2015	Q4 2016	% change vs. Q4 2015	Q1 2017	% change vs. Q1 2016
MabThera/Rituxan	479	5	482	5	468	4	450	-1	465	1
Herceptin	525	2	523	3	521	4	486	-2	522	3
Avastin	471	2	473	4	458	-1	439	-4	446	-3
Perjeta	149	65	161	56	163	42	155	22	176	21
Actemra/RoActemra	131	17	143	21	142	18	142	14	147	17
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Tamiflu	20	78	11	*	7	*	63	*	13	-30
Kadcyla	83	13	84	2	83	1	81	-6	84	5
Tarceva	48	-18	44	-27	43	-19	39	-25	37	-22
Esbriet	45	36	41	9	49	33	44	-4	42	-2
Pulmozyme	31	6	30	5	30	10	31	6	32	10
CellCept	43	-3	46	2	43	-1	44	-4	43	3
Mircera	21	-7	22	-2	22	0	22	4	22	3
Tecentriq	-	-	-	-	1	-	1	-	2	-
Xeloda	9	-31	8	-17	8	-23	7	-30	6	-28
Madopar	24	-1	25	2	25	2	25	5	23	0
NeoRecormon/Epogin	36	-10	35	-11	36	-7	34	-8	32	-8
Rocephin	13	-13	7	-13	6	2	11	26	13	-3

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015	Q3 2016	% change vs. Q3 2015	Q4 2016	% change vs. Q4 2015	Q1 2017	% change vs. Q1 2016
MabThera/Rituxan	62	12	72	12	77	9	80	11	62	-3
Herceptin	67	5	79	4	79	2	84	7	67	-4
Avastin	192	7	206	-2	213	-6	223	-5	181	-8
Perjeta	23	18	27	10	27	4	31	17	26	7
Actemra/RoActemra	60	14	70	13	75	10	79	14	64	4
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Tamiflu	60	4	4	*	12	*	46	243	65	5
Kadcyla	17	27	20	20	18	4	20	4	16	-9
Tarceva	22	0	27	3	27	-9	28	4	22	-4
Esbriet	-	-	-	-	-	-	-	-	-	-
Pulmozyme	-	-	-	-	-	-	-	-	-	-
CellCept	15	11	18	16	18	12	20	14	17	9
Mircera	45	4	55	2	56	-1	63	3	43	-6
Tecentriq	-	-	-	-	-	-	-	-	-	-
Xeloda	25	12	29	16	28	8	29	4	25	-3
Madopar	3	-7	5	-2	4	-6	4	-5	4	-2
NeoRecormon/Epogin	10	-12	12	-12	12	-16	13	-6	10	-6
Rocephin	6	-10	7	-19	8	-11	9	-7	6	-15

* Over 500%

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015	Q3 2016	% change vs. Q3 2015	Q4 2016	% change vs. Q4 2015	Q1 2017	% change vs. Q1 2016
MabThera/Rituxan	306	11	300	3	305	0	308	3	327	4
Herceptin	482	7	477	8	474	10	476	1	487	0
Avastin	268	27	282	18	290	14	304	13	292	7
Perjeta	43	65	49	121	54	78	59	50	65	47
Actemra/RoActemra	50	10	51	23	51	18	56	22	57	7
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	11	13	11	3	12	12	12	-10	11	0
Tamiflu	36	35	16	9	11	-24	41	20	36	-4
Kadcyla	22	56	23	53	28	44	36	38	33	49
Tarceva	52	-14	50	-15	40	-27	44	-11	43	-18
Esbriet	6	4	5	-8	6	-17	3	-43	7	10
Pulmozyme	17	22	26	38	21	-12	25	17	18	3
CellCept	86	-8	77	-4	79	-4	80	-4	77	-11
Mircera	52	0	46	18	56	-29	52	70	50	-5
Tecentriq	-	-	-	-	-	-	1	-	2	-
Xeloda	72	-13	70	-6	74	-6	68	-16	67	-8
Madopar	44	39	39	-7	45	6	47	7	59	30
NeoRecormon/Epogin	33	-18	35	-5	35	-5	37	-7	35	4
Rocephin	63	12	61	30	60	22	46	-15	55	-10

* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others